Rockwell Medical Technologies (NASDAQ: RMTI) reported Q3 EPS of ($0.10), in-line with the analyst estimate of ($0.10). Revenue for the quarter came in at $13.7 million versus the consensus estimate of $13.4 million.

"We achieved a strong 3rd quarter and then two significant accomplishments; our successful confirmatory vote on Triferic from the FDA Advisory Committee and our commercialization agreement with Baxter," stated Mr. Robert L. Chioini, Founder, Chairman and CEO of Rockwell Medical. "The Advisory Committee's majority vote recommending Triferic as a therapy to treat iron loss and maintain hemoglobin in hemodialysis patients adds to our conviction that this drug can make a positive difference for ESRD patients in addressing this unmet need. We remain committed to working with the FDA on completing its review for marketing approval of Triferic. Our exclusive distribution agreement with Baxter, a global leader in selling dialysis products, enabled us to monetize a valuable asset and strengthen our balance sheet while also providing dialysis patients and service providers expanded access to our market leading products in new territories. These two recent milestone events, in addition to our strong sales and margin improvements in the third quarter, give us great momentum moving forward."

For earnings history and earnings-related data on Rockwell Medical Technologies (RMTI) click here.